ArticleLasers in medical science2025
Application of transurethral blue laser vaporization of the prostate in patients aged 80 and above: a single-center clinical analysis of 157 cases.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of blue laser vaporization of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis.The Canadian journal of urology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aims to assess the safety and effectiveness of transurethral blue laser prostate vaporization (BVP) for elderly patients (≥80 years) with benign prostatic hyperplasia (BPH), focusing on clinical outcomes, recovery, and complications. A retrospective analysis was performed on 157 BPH patients aged ≥ 80 years who underwent BVP at a single center between May 2023 and May 2025. The patients' general condition was assessed through comorbidities and concurrent surgeries, postoperative outcomes were evaluated through the International Prostate Symptom Score (IPSS), and surgical safety was evaluated based on operative time and postoperative blood tests. The mean age was 83.97 ± 3.63 years, with an average prostate volume of 63.34 ± 34.95 ml. Patients had an average of 2.5 comorbidities, and 26.1% required additional surgical interventions. The average procedure time was 28.2 ± 12.1 min, with a median hospital stay of 9 days. Postoperative IPSS scores decreased significantly to 4.3 ± 3.5. Mild red blood cell loss (hemoglobin decreased by 6.1%, p < 0.001) and a significant inflammatory response (neutrophils increased by 26.5%, p < 0.001) were observed, but no transfusion was needed. Transurethral blue laser prostate vaporization is a safe and effective option for elderly BPH patients with multiple comorbidities, offering significant symptom improvement with minimal postoperative complications.
Indexed as
Identifiers
41420775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.